These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 25582072)

  • 1. Reasons for discontinuation of recommended therapies according to the patients after acute coronary syndromes.
    Gencer B; Rodondi N; Auer R; Räber L; Klingenberg R; Nanchen D; Carballo D; Vogt P; Carballo S; Meyer P; Matter CM; Windecker S; Lüscher TF; Mach F
    Eur J Intern Med; 2015 Jan; 26(1):56-62. PubMed ID: 25582072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing prevention and guideline-concordant care in Montenegro.
    Knežević B; Musić L; Batrićević G; Bošković A; Bulatović N; Nenezić A; Vujović J; Kalezić M
    Int J Cardiol; 2016 Aug; 217 Suppl():S32-6. PubMed ID: 27381861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence-based medication use among Chinese patients with acute coronary syndromes at the time of hospital discharge and 1 year after hospitalization: results from the Clinical Pathways for Acute Coronary Syndromes in China (CPACS) study.
    Bi Y; Gao R; Patel A; Su S; Gao W; Hu D; Huang D; Kong L; Qi W; Wu Y; Yang Y; Turnbull F;
    Am Heart J; 2009 Mar; 157(3):509-516.e1. PubMed ID: 19249422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Self-reported use of evidence-based medicine and smoking cessation 6 - 9 months after acute coronary syndrome: a single-centre perspective.
    Griffiths B; Lesosky M; Ntsekhe M
    S Afr Med J; 2014 Jun; 104(7):483-7. PubMed ID: 25214049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study.
    Eagle KA; Kline-Rogers E; Goodman SG; Gurfinkel EP; Avezum A; Flather MD; Granger CB; Erickson S; White K; Steg PG
    Am J Med; 2004 Jul; 117(2):73-81. PubMed ID: 15234641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence with secondary prevention medications after acute myocardial infarction: Insights from the TRANSLATE-ACS study.
    Mathews R; Wang TY; Honeycutt E; Henry TD; Zettler M; Chang M; Fonarow GC; Peterson ED;
    Am Heart J; 2015 Jul; 170(1):62-9. PubMed ID: 26093865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hospital revascularisation capability and quality of care after an acute coronary syndrome in Switzerland.
    Welker J; Auer R; Gencer B; Muller O; Cornuz J; Matter CM; Mach F; Windecker S; Rodondi N; Nanchen D
    Swiss Med Wkly; 2016; 146():w14275. PubMed ID: 26859223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilization of evidence-based therapy for the secondary prevention of acute coronary syndromes in Australian practice.
    Vermeer NS; Bajorek BV
    J Clin Pharm Ther; 2008 Dec; 33(6):591-601. PubMed ID: 19138236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge.
    Lee HY; Cooke CE; Robertson TA
    J Manag Care Pharm; 2008 Apr; 14(3):271-80. PubMed ID: 18439049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-hospital management and mortality in elderly patients with non-ST-segment elevation acute coronary syndromes treated in centers without on-site invasive facilities.
    Dziewierz A; Siudak Z; Rakowski T; Zdzienicka J; Dykla D; Mielecki W; Dubiel JS; Dudek D
    Cardiol J; 2008; 15(5):451-7. PubMed ID: 18810721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal medical therapy at discharge in patients with acute coronary syndromes: temporal changes, characteristics, and 1-year outcome.
    Yan AT; Yan RT; Tan M; Huynh T; Soghrati K; Brunner LJ; DeYoung P; Fitchett DH; Langer A; Goodman SG;
    Am Heart J; 2007 Dec; 154(6):1108-15. PubMed ID: 18035083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Under-use of secondary prevention medication in acute coronary syndrome patients treated with in-hospital coronary artery bypass graft surgery.
    Looi KL; Chow KL; Looi JL; Lee M; Halliday S; White H; Ellis C
    N Z Med J; 2011 Sep; 124(1343):18-27. PubMed ID: 21964009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of a P2Y12 Inhibitor Copayment Reduction Intervention With Persistence and Adherence With Other Secondary Prevention Medications: A Post Hoc Analysis of the ARTEMIS Cluster-Randomized Clinical Trial.
    Fanaroff AC; Peterson ED; Kaltenbach LA; Cannon CP; Choudhry NK; Henry TD; Anstrom KJ; Cohen DJ; Fonseca E; Khan ND; Fonarow GC; Wang TY
    JAMA Cardiol; 2020 Jan; 5(1):38-46. PubMed ID: 31721978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utilization of secondary prevention therapies in patients with nonobstructive coronary artery disease identified during cardiac catheterization: insights from the National Cardiovascular Data Registry Cath-PCI Registry.
    Maddox TM; Ho PM; Roe M; Dai D; Tsai TT; Rumsfeld JS
    Circ Cardiovasc Qual Outcomes; 2010 Nov; 3(6):632-41. PubMed ID: 20923997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parabolas of medication use and discontinuation after myocardial infarction--are we closing the treatment gap?
    Hudson M; Richard H; Pilote L
    Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):773-85. PubMed ID: 17486661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Impact of different intervention models on adherence to secondary prevention therapies in patients with acute coronary syndrome].
    Liu J; Wang W; Liu J; Wang Y; Qi Y; Sun JY; Zhao D
    Zhonghua Xin Xue Guan Bing Za Zhi; 2018 Feb; 46(2):124-130. PubMed ID: 29495236
    [No Abstract]   [Full Text] [Related]  

  • 17. Use and cost of branded and generic drugs in patients with coronary heart disease--results from a prospective survey of 1008 patients in two London hospitals.
    Corp EV; Antoniou S; Wright PG; Khachi H; Vercaeren S; Wald DS
    QJM; 2009 Dec; 102(12):843-9. PubMed ID: 19828644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of evidence-based cardiac drug therapy on mortality in patients with acute coronary syndrome: Findings from the Gulf COAST registry.
    Al-Zakwani I; Zubaid M; Alsheikh-Ali AA; Almahmeed W; Rashed W
    Cardiovasc Ther; 2018 Dec; 36(6):e12463. PubMed ID: 30079461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors, cost, and outcomes of patients with acute coronary syndrome who receive optimal secondary prevention therapy: results from the antiplatelet treatment observational registries (APTOR).
    Zeymer U; Berkenboom G; Coufal Z; Belger M; Sartral M; Norrbacka K; Bakhai A;
    Int J Cardiol; 2013 Dec; 170(2):239-45. PubMed ID: 24225199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utilization of Evidence-Based Secondary Prevention Medications at the Time of Discharge in Patients with Acute Coronary Syndrome (ACS) in Qatar.
    El-Hajj MS; Saad A; Al-Suwaidi J; Al-Marridi WZ; Elkhalifa DH; Mohamed AA; Mahfoud ZR
    Curr Vasc Pharmacol; 2016; 14(4):394-403. PubMed ID: 26916397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.